12/19
09:58 am
kzr
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Company from $11.00 to $9.00. They now have an "equal weight" rating on the stock.
Medium
Report
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Company from $11.00 to $9.00. They now have an "equal weight" rating on the stock.
12/2
08:06 am
kzr
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
11/14
10:12 am
kzr
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $11.00. They now have an "equal weight" rating on the stock.
Low
Report
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $11.00. They now have an "equal weight" rating on the stock.
11/13
08:36 am
kzr
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "market perform" rating re-affirmed by analysts at William Blair.
Medium
Report
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "market perform" rating re-affirmed by analysts at William Blair.
11/12
04:41 pm
kzr
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/12
04:01 pm
kzr
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Low
Report
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
11/5
10:58 am
kzr
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
Low
Report
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
10/28
08:30 am
kzr
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
Medium
Report
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
10/17
01:43 pm
kzr
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study [Yahoo! Finance]
Low
Report
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study [Yahoo! Finance]
10/17
08:35 am
kzr
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
Medium
Report
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
10/17
08:30 am
kzr
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
Medium
Report
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
10/15
01:45 pm
kzr
What Makes Kezar Life Sciences (KZR) a New Buy Stock [Yahoo! Finance]
Low
Report
What Makes Kezar Life Sciences (KZR) a New Buy Stock [Yahoo! Finance]
10/14
08:41 am
kzr
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
10/10
08:30 am
kzr
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
Medium
Report
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
10/7
08:53 am
kzr
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths [Yahoo! Finance]
Medium
Report
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths [Yahoo! Finance]
10/7
05:10 am
kzr
FDA places hold on Kezar Life Sciences' trial for lupus nephritis treatment [Yahoo! Finance]
Low
Report
FDA places hold on Kezar Life Sciences' trial for lupus nephritis treatment [Yahoo! Finance]
10/4
05:00 pm
kzr
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
Low
Report
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
10/2
08:08 am
kzr
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
High
Report
Kezar Life Sciences, Inc. (NASDAQ: KZR) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
10/1
05:33 am
kzr
Kezar Life Sciences suspends subject enrolment in trial of lupus nephritis drug [Yahoo! Finance]
Medium
Report
Kezar Life Sciences suspends subject enrolment in trial of lupus nephritis drug [Yahoo! Finance]
9/30
08:30 am
kzr
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
High
Report
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients